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doi:10.1Objective:Nitinol attachment rings (devices) used to attach mechanical aortic valve prostheses suturelessly were
studied in long-term (90 days) pig experiments.
Methods: The aortic valve was removed and replaced by a device around a St Jude Medical mechanical valve
prosthesis in 10 surviving pigs. Supravalvular angiography was done at the end of the operation. No coumarin
derivates were given.
Results: No or minimal aortic regurgitation was confirmed in all surviving pigs at the end of the operation. Total
follow-up was 846 days. In 4 pigs, follow-up was shorter than 90 days (28–75 days); the other 6 pigs did reach 90
days’ survival or more. Repeat angiography in 4 pigs at the end of follow-up confirmed the unchanged position of
the device at the aortic annulus, without aortic regurgitation. At autopsy, in all pigs the devices proved to be well
grown in at the annulus, covered with endothelium, and sometimes tissue overgrowth related to not using cou-
marin derivates. There was no case of para-device leakage, migration, or embolization. No damage to surrounding
anatomic structures or prosthetic valves was found.
Conclusions: Nitinol attachment rings can be used to replace the aortic valve suturelessly with St Jude Medical
mechanical aortic valve prostheses, without para-device leakage, migration, or damage to the surrounding tissues,
in long-term pig experiments during a follow-up of 90 days or more. Refraining from anticoagulation in pigs with
mechanical valve prostheses can lead to tissue overgrowth of the valve prosthesis. Further studies are needed to
determine long-term feasibility of this method in human beings. (J Thorac Cardiovasc Surg 2011;141:1231-7)B
SSupplemental material is available online.E
T
/Video clip is available online.
Hand-suturing is the current standard for attaching an aortic
valve prosthesis to the anatomic aortic valve annulus. How-
ever, it consumes a relatively great deal of time, particularly
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The Journal of Thoracic and Carmally invasive valve surgery less favorable. The first valve
prosthesis implanted in the human being by Hufnagel in
1952 (as reported by Hufnagel and Harvey1) was a sutureless
valve, and sutureless Magovern–Cromie valves were used
for aortic and mitral valve replacements for many years.2
Currently, there is renewed interest in sutureless aortic valve
implantation, mostly by mounting a biological aortic valve
into a metal stent and compressing it into a catheter
sleeve.3-8 However, with this technique the diseased valve
is not removed, and current valved stents do not yet result
in early outcomes comparable with surgically removed
and replaced heart valves.9,10 Previously, we11 have shown
that it is feasible to use Nitinol attachment rings to attach me-
chanical aortic valve prostheses solidly to the aortic valve
annulus after removal of the original aortic valve in acute
pig studies and that such rings can withstand a high pulling
force.11 Our intention with this study was to investigate the
long-term (90-day) outcome in pigs of using such Nitinol at-
tachment rings to suturelessly replace the aortic valve by a St
Jude Medical mechanical aortic valve prosthesis (St Jude
Medical, Inc, Minneapolis, Minn) approved by the Food
and Drug Administration (FDA).MATERIALS AND METHODS
After extensive ex vivo and short-term in vivo testing,11 long-term in
vivo experiments were performed in pigs from February 2007 until Junediovascular Surgery c Volume 141, Number 5 1231
Abbreviations and Acronyms
FDA ¼ Food and Drug Administration
LV ¼ left ventricular
LVH ¼ left ventricular hypertrophy
VAR ¼ valve attachment ring
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S2009 (Figure E1) with Nitinol sutureless attachment rings around
suturering-denuded 19- or 21-mm FDA-approved St Jude Medical demo
mechanical aortic valve prostheses (device pigs). In the last experiments
the aortic valve was replaced by an unchanged 19-mm FDA-approved St
Jude Medical demo mechanical aortic valve prosthesis using standard
hand-suturing techniques (control pigs). The follow-up of the surviving
10 device and 1 control pigs ended in September 2009 and is described in
more details.Devices, Stretching, and Activation
The proprietary valve attachment rings (VARs) were manufactured from
Nitinol memory metal (Endosmart GmbH, Stutensee, Germany) and had a si-
nusoidal shape with a flexible upper and lower flange. The bare Nitinol ring
was almost completely covered by textile (Jotec GmbH, Hechingen, Ger-
many), while maintaining full valve rotatability (Figure 1, A and B, Video
E1). After sterilization, the device was mounted on the applicator, and the
flanges were manually stretched in iced saline. Unintended early expansion
during navigation at room temperature was prevented by placement of 1 to 3
stretching sutures through the textile covering of the flanges and fixation to
the applicator, which was kept in iced saline until its use. After positioning
and rewarming, the ring fixed itself by clamping the valve annulus tissue be-
tween its upper and lower flanges. In the first 5 pigs in the device group, 21-
mm St Jude mechanical aortic valve prostheses were used, and in the last 5,
19-mm St Jude mechanical aortic valve prostheses were used. VARs with
a fixed upper flange and a flexible lower flange were also developed, with
the advantage that larger unchanged mechanical or biological valve prosthe-
ses can be mounted on top of such rings (Figure E2, A and B, Video E2). A
fixed upper flange can work as a self-blocking mechanism to facilitate
‘‘blind’’ navigation of the VAR to the annulus. However, in this series of
experiments only rings with flexible upper and lower flanges were used.Applicators
In 7 cases the device was mounted on an applicator with 2 separate
holding arms (Kiki Ingenieursgesellschaft GmbH, Malsch, Germany)
(Figure 2, A). In 1 case an applicator was used with a temperature-
regulating fluid-recirculating closed circuit (Technical University Delft,
Delft, The Netherlands) (Figure 2, B). Although this recirculating applica-
tor proved feasible, it was not used more frequently because its large heads
were obliterating the surgical view and damaging the aorta. Finally, a sim-
ple holding applicator was developed and used in 2 later cases, consisting
of a holder with a ring sutured on top of the valve housing (Instrumenta-
tion Department, Catharina Hospital, Eindhoven, The Netherlands)
(Figure 2, C).Surgical Procedures and Postoperative Investigations
In anesthetized and ventilated young female pigs (mean weight, 74.8 kg;
range, 68–77 kg), a median sternotomy was performed. After hepariniza-
tion, the animal was placed on full bypass with arterial cannulation in the
ascending aorta or aortic arch and venous cannulation with a single cannula
through the right atrial appendage. Left ventricular (LV) decompressionwas
achieved through the LV apex, the aorta was crossclamped, and a single shot
of cold St Thomas’ Hospital crystalloid cardioplegic solution was adminis-1232 The Journal of Thoracic and Cardiovascular Surtered. The aortic valve leaflets were completely removed. To compensate for
mismatch between the diameter of the annulus and the device, having only
one size prototype available per experiment, and the annular diameter being
variable and flexible in young and healthy pigs, we placed a single circular
annular suture. Because the view inside the small aorta was hindered by the
device and applicator, and to give the device its optimal rotation, we used
guiding sutures to assist in navigating the device to the annulus. These su-
tures were placed in themiddle of sinuses, led through the textile covering of
the VAR upper flange, and pulled during its positioning. After positioning,
the annular suture was pulled and tied, and the stretching sutures were cut
and retracted. The device was activated by warm (about 45C) sterile saline
over the heart in 5 cases, by circulation of warm saline through a recirculat-
ing applicator in 1 case, and by flushing the aorta with warm sterile saline in
4 cases. During reperfusion, inotropic and antiarrhythmic drugs were given,
as indicated. Heart and valve function were evaluated by transesophageal
echocardiography before bypass, before weaning off bypass, and after by-
pass in the initial cases. Supravalvular angiographywas performed after per-
fusion through one of the carotid arteries by a cardiologist and was repeated
under anesthesia before the pig was humanely killed in cases that reached 90
days’ survival. Aortic regurgitation was graded by an independent cardiol-
ogist (Guus Breuren, MD) as 0 if absent and 1þ to 4þ if present.12 During
follow-up, the only anticoagulation given was 160 mg of acetylsalicylic
acid twice a day and 75 mg of clopidogrel once a day. All animals under-
went an autopsy, including macroscopic and histologic examination of
the heart and organs. Position and function of the device were determined
from both sides, and paravalvular leakage was sought with a 1-mm probe.
Tissue overgrowth was graded as 0 if not covering the VAR’s textile, 1 if
covering the VAR’s textile but not the valve ostium, 2 if covering less
than 25%, 3 between 25% and 50%, and 4 more than 50% of the valve
ostium. All long-term animal tests were approved along the Animal Re-
search Ethics regulations of the institution. The animals received care in
compliance with the European Convention on Animal Care and the Guide
for the Care and Use of Laboratory Animals, as published by the US Na-
tional Institutes of Health (NIH Publication No. 85-23, revised 1996).
RESULTS
Procedures and Early Outcome
In 13 device experiments and 1 control experiment the an-
imals did not survive the operation or the first 24 hours there-
after, for different or combined reasons. In 3 cases, we could
not place the device because it was too large (n ¼ 2) or be-
cause a valve was damaged valve leaflet during loading
(n ¼ 1). Device–pig mismatch initially occurred often, be-
cause only 1 relatively large (21-mm valve) prototype was
available, with a relatively thick self-made textile covering,
which made implantation of the device impossible or very
difficult, with irreparable damage of the aorta. In 5 cases
there were difficulties with the aortotomy, with bleeding,
or with compromised right coronary artery flow by the aorta
closing sutures. In 4 cases we deviated from the operative
protocol by trying to omit stretching, guiding, or annular su-
tures. Other problems included wrong sterilization method
of the device in 2, accidental removal of the aortic cannula
in 1, and retroperitoneal bleeding in another case. Also, 1
control animal did not survive as a result of a prolonged pro-
cedure owing to poor exposure of the aortic valve. There has
been no early operative death directly related to the presence
or action of the device, once implanted correctly. In all non-
surviving pigs in which the device could be implanted, the
aortic annular position of the device has been confirmedgery c May 2011
FIGURE 1. A, Suturering-denuded 19-mm St Jude Medical mechanical aortic valve prosthesis inside textile-covered Nitinol attachment ring with flexible
upper and lower flange (device), in warm expanded shape (view from above). B, Same device as in A, in stretched cold shape (side view).
Berreklouw et al Evolving Technology/Basic Scienceby supravalvular angiography and/or autopsy. In the long-
term survivors, in 2 cases the flanges started to expand too
early, and in 5 cases the aortotomy tore out, leading to its
complicated closure. In 4 cases the temporary stretching su-
tures broke off when we attempted to retract them, and they
could not be removed completely. Once the device was in
place, the actuation with warm saline, or recirculating appli-
cator, worked instantly in all cases. In the surviving pigs in
the device group the average aortic crossclamp time was
49.2 minutes (range, 39–75 minutes), and the average perfu-
sion time was 77.9 minutes (range, 54–122 minutes). Clos-
ing the aorta took at least 30 minutes in all cases.FIGURE 2. A, Applicator with 2 movable holding arms inside same device as
plicator with 2 movable holding arms inside same device as in Figure 1, in stre
in the same device as in Figure 1, in stretched cold shape (side view).
The Journal of Thoracic and CarLate Outcome
Among the 10 pigs surviving long term in the device
group, the mean follow-up was 84.6 days (range, 28–148
days), with a total of 846 days, while 1 surviving control
pig was followed up for 90 days (Table 1). Four device an-
imals did not reach the predetermined 90 days’ follow-up
period. One pig was humanely killed after 28 days because
of bacterial aortic valve endocarditis. One pig drowned acci-
dentally after 62 days when it fell through a manhole cover.
Two pigs were humanely killed because of congestive heart
failure at 69 and 75 days. The other 6 device and 1 control
pigs did reach the predetermined 90 days’ follow-up period.in Figure 1, in stretched cold shape (side view). B, Recirculating fluid ap-
tched cold shape (side view). C, Simple holding applicator sutured on top
diovascular Surgery c Volume 141, Number 5 1233
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TABLE 1. Outcome data
D/C Preop weight (kg)
Grade AI
Cause of late death Survival (d) Autopsy weight (kg)
Tissue overgrowth
LVH AutopsyPerop angio Late angio Aortic side LV side
D1 68 1 – 1 99 103 1 2 0 1
D2 75 0 1 1 91 120 2 3 1 2
D3 74 0 – 2 69 96 1 3 0 3
D4 70 1 1 1 148 99 1 2 0 0
D5 76 2 – 2 75 87 1 1 0 4
D6 77 1 – 3 62 100 2 1 0 0
D7 77 0 0 1 92 127 4 3 1 0
D8 68 1 – 4 28 75 1 1 1 5
D9 68 1 1 1 92 137 2 2 0 0
D10 72 2 1 1 90 125 1 2 0 0
C1 68 1 1 1 90 120 1 2 0 0
D, Device; C, control; AI, Aortic insufficiency; LV, left ventricular; LVH, left ventricular hypertrophy. Cause of death: 1 ¼ humanely killed at end of follow-up, 2 ¼ heart failure,
3 ¼ accidental drowning, 4 ¼ endocarditis. Autopsy: 0 ¼ no gross abnormalities, 1 ¼ large atrial septal defect, 2¼ left ventricular and right ventricular hypertrophy, 3¼ chronic
heart failure with tissue overgrowth, 4 ¼ chronic heart failure with broken stretching suture, 5 ¼ endocarditis.
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SAfter initial recovery from surgery, all animals behaved and
grew normally. There have been no signs of thromboem-
bolic complications or other valve-related complications.
The surviving pigs in the device group showed an average
weight increase of 407 g per day, with mean weight of
122 kg around 90 days’ survival.Angiographic Examinations
In all device and control pigs (with the exception of 1 case
in which it was technically not possible), supravalvular an-
giography was performed after weaning from bypass and
confirmed that the device, with respect to the valve, was at
its desired position at the aortic annulus and the coronary ar-
teries were patent. Angiograms at surgery showed grade
0 aortic regurgitation in 3, grade 1þ in 5 (Figure 3, A), and
grade 2þin 2 surviving device pigs. It was not possible to dif-
ferentiate whether regurgitation was caused by para-device
leakage or by backflow through the demo valves used. In
4 of the device pigs and 1 control pig the supravalvular an-
giogram was repeated after 90 days of follow-up, just beforeFIGURE 3. A, Peroperative supravalvular angiogram of device in aortic annul
after 90 days, showing same device as in Figure 3, A, with grade 1þaortic regu
1234 The Journal of Thoracic and Cardiovascular Surthe animals were humanely killed. In all 4 of these device
pigs, the late angiogram demonstrated an unchanged nonmi-
grated position of the device at the aortic annulus, with grade
0 regurgitation (Figure 3, B) in 1 case and grade 1þregurgi-
tation in 3 cases. The control pig did show grade 1þregurgi-
tation at the operation and when humanely killed. In 1 device
pig, only fluoroscopy was performed when the animal was
humanely killed, and this demonstrated an unchanged de-
vice position and normal valve blade movements (Table 1).Pathologic Examinations
Autopsy of the pig with endocarditis that was humanely
killed 28 days postoperatively showed a normal position
of the device, with vegetations at the ventricular side of
the valve prosthesis, but without para-device abcesses.
There was left ventricular hypertrophy (LVH), likely caused
by vegetations that almost obliterated the valve ostium from
below. Autopsy of the drowned pig 62 days after the
operation revealed no abnormalities of the device at its annu-
lar position. Postmortem examination of the 2 pigs withar position, with grade 1þaortic regurgitation. B, Supravalvular angiogram
rgitation.
gery c May 2011
FIGURE 4. A, Device after 94 days, from aortic side, with grade 1 tissue overgrowth. B, Same device as in Figure 4, A, from left ventricular side with grade 2
tissue overgrowth. C, Hand-sutured control valve, after 90 days, from aortic side with grade 1 tissue overgrowth. D, Same device as Figure 4,C, from left
ventricular side with grade 2 tissue overgrowth.
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showed normal position of the device in both. In 1 animal,
grade 3 tissue overgrowth at the ventricular side was ob-
served. In the other pig, a remaining piece of broken stretch-
ing suture was present, likely having caused aortic
regurgitation. Neither animal demonstrated signs of LVH.
At all autopsies, including those in the 4 pigs that did not
reach 90 days’ follow-up, the device remained well attached
at its annular position without migration or para-device leak-
age. In all device cases, the textile around the VAR was cov-
ered with a layer of endothelial cells. The amount of tissue
overgrowth was at the aortic side, grade 1 in 6 cases, grade
2 in 3 cases, and grade 4 in 1 case (Table 1 and Figure 4, A
and B). From the LV side the tissue overgrowth was grade 1
in 3 cases, grade 2 in 4 cases, and grade 3 in 3 cases. The
overgrowth was not more than grade 1 or 2 at the aortic
side in 90% and at the LV side in 70% of the cases. Also,
the control valve showed grade 1 tissue overgrowth at the
aortic side and grade 2 at the LV side (Figure 4, C and D).
It seemed that tissue overgrowth was more pronounced
with an increasing duration of follow-up. Although the os-
tium of the valve prosthesis has been limited by tissue over-
growth in a number of cases, no intrinsic abnormalities were
seen at the valve prosthesis or its leaflets. Signs of LVHwere
found in 3 pigs in the device group, with vegetations below
the device in the pig with valvular endocarditis and in 2 pigs
with more than grade 2 overgrowth at both sides of the de-
vice. In none of the device pigs was macroscopic damage
found to surrounding tissues, including the coronary arteries,
interventricular septum, and anterior mitral valve. No throm-
boemboli were found in the heart, vessels, or distal organs.The Journal of Thoracic and CarDISCUSSION
This study demonstrates that Nitinol attachment rings
around suture-denuded mechanical aortic valves remain
well attached to the aortic valve annulus, without peri-
device leakage or damage to the valve prosthesis or sur-
rounding tissues, not only during acute pig studies,11 but
also during follow-up of 90 days or more. A certain degree
of tissue overgrowth of the devices was found, but not more
than grade 2 at the aortic side in 90% and at the LV side in
70% of the cases, and not apparently different from the sin-
gle control case. Similar tissue overgrowth has been
described in pigs in which the mitral valve was replaced
by a mechanical valve prosthesis and is related to level of an-
ticoagulation with coumarin derivates.13 High-dose anticoa-
gulation results in low-grade tissue overgrowth with high
mortality, and no coumarin derivates, as in our study, results
in high-grade tissue overgrowth with low mortality.13
Although peroperative angiography of our (demo) valves
demonstrated grade 2þ aortic regurgitation in 2 cases, late
angiographic examinations performed in 1 of these cases
did show grade 1þ regurgitation, and at autopsy no para-
device leakage was demonstrated in either. In animals that
did not survive the operation there was no direct relation
to the sutureless valve replacement method as such, but
mainly to problems with closing the aortotomy. In a number
of cases these problems were related to the device–pig mis-
match, inasmuch as initially we had only one relatively large
device with a 21-mm valve prosthesis and relatively thick
textile covering available. Subsequently, smaller 19-mm
valve prostheses were used, and the thickness of the textile
covering has been further diminished. Deviations from thediovascular Surgery c Volume 141, Number 5 1235
Evolving Technology/Basic Science Berreklouw et al
E
T
/B
Soperative protocol by trying to omit stretching sutures, guid-
ing sutures, or annular sutures was another reason for early
failures and part of our learning process. In a number of
cases the stretching sutures broke off, potentially causing
prosthetic valve malfunction. This method of temporarily
stretching the flanges needs to be improved by mechanical
means. Although the use of guiding and annular sutures
was shown to be necessary in this pig model, that is not to
say that all these will be required in human beings, in
whom exposure of the aortic valve is better, diseased annuli
stiffer, and more devices sizes will be available. In this series
of experiments, only prototypes of attachment rings were
used with both flexible upper and lower flanges. The valve
prosthesis was positioned within the rings, which were
placed within the annulus, potentially diminishing effective
valve orifice, especially in small sizes. Other prototypes with
fixed upper and flexible lower flanges have been developed
as well. With this latter prototype it is possible to place an
oversized, unchanged valve prosthesis on top of the fixed
upper flange supra-annularly. Such prototypes have been
successfully tested by us in the aortic position in vitro and
in the mitral position during acute pig experiments (manu-
script submitted to this Journal), but were not used in these
experiments because of the small aorta size in our pigs. Cur-
rently, there is a strong interest in self-expanding, or balloon-
dilated, catheter-based sutureless biological aortic valve
implants that are mounted within a stent.6-10 These valved
stents are implanted by radial expansion within the calcified
remnants of the pre–balloon-dilated diseased valve and
show high incidence of postprocedure regurgitation.7,8,14
Percutaneous balloon aortic valvuloplasty as such carries
a high rate of serious complications, including cerebral.15
Balloon-dilatable stents will demonstrate no active radial
expansion force once they have been dilated. Also, a self-
expanding stent will exert zero radial expansion force once
the valve prosthesis that is sutured within the stent has fully
expanded. For this reason, certain valved stents are attached
distally in the ascending aorta, away from the valve annu-
lus,16 and it is common17 and recommended18 to oversize
valved stents to diminish para-device leakage. This oversiz-
ing may result in less than full expansion of valve prostheses
and, together with noncircular expansion within calcium,19
these factors may lead to nonlaminar flow, potentially result-
ing in accelerated structural valve degeneration. Durability of
(balloon-dilated) valves within a stent is currently still uncer-
tain. On the contrary, the attachment rings are sized according
to the annular diameter of the completely removed diseased
valve. The ring attaches itself by clamping the annulus in
a longitudinal direction, without radial expansion, which
allows use of fully expanded biological or mechanical valve
prostheses with proven long-term durability.20
Valved stents have a high profile that, together with the
valve dilatation method as such, can cause damage to the
mitral valve, coronary ostia, aorta, left ventricle, and conduc-1236 The Journal of Thoracic and Cardiovascular Surtion tissue.9 The continuous radial expansion of (oversized)
self-expandable valved stents at the aortic annular level results
in a 30% to 40% incidence of conduction abnormalities, ne-
cessitating subsequent pacemaker implantation.21 Recently, 2
self-expanding valved stents were introduced for clinical in-
vestigation. These stents have the advantage that they can
be applied after surgical removal of the diseased valve,22,23
but further these products carry potentially the same
disadvantages as self-expanding catheter-based valved stents.
Many of these disadvantages may be prevented by using
Nitinol attachment rings to replace heart valves suturelessly.
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FIGURE E1. Operative research team: Maria Olieslagers, Sara van de Wiele, Stefaan Bouchez, Filip De Somer, Eric Berreklouw, and Bart Koene (left to
right)
FIGUREE2. A, Unchanged 19-mm Edwards Perimount biological aortic valve prosthesis on top of textile-covered Nitinol attachment ring with rigid upper
and flexible lower flange (device), in warm expanded shape (side view). B, Same device as in A, in cold stretched shape (side view).
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